Hepcidin is a key hormone that is involved in the control of iron homeostasis in the body. Physiologically, hepcidin is controlled by iron stores, inflammation, hypoxia, and erythropoiesis. The regulation of hepcidin expression by iron is a complex process that requires the coordination of multiple proteins, including hemojuvelin, bone morphogenetic protein 6 (BMP6), hereditary hemochromatosis protein, transferrin receptor 2, matrkapase-2, neogenin, BMP receptors, and transferrin. Misregulation of hepcidin is found in many disease states, such as the anemia of chronic disease, iron refractory iron deficiency anemia, cancer, hereditary hemochromatosis, and ineffective erythropoiesis, such as β-thalassemia. Thus, the regulation of hepcidin is the subject of interest for the amelioration of the detrimental effects of either iron deficiency or overload.

Discovery and function of hepcidin in iron homeostasis
Hepcidin is a key peptide hormone that regulates iron homeostasis in chordates. Hepcidin was initially characterized as an antimicrobial peptide in a mass spectrometry–based search for cysteine-rich defensin-like peptides in blood (1) and in urine (2). However, both groups showed that hepcidin displays only a weak antimicrobial activity. Further, unlike defensins, which vary in sequence among species, hepcidin is highly conserved from zebrafish to humans. Shortly after hepcidin was described, subjective hybridization studies comparing the livers of normal and iron overloaded mice established a connection between iron loading and increased hepcidin mRNA (3, 4). The fundamental insight into hepcidin’s role in iron homeostasis came in 2004 with the discovery that hepcidin acts to decrease the transport of iron out of intestinal epithelial cells, further lowering iron in the blood. In addition, a high concentration of hepcidin in the blood decreases the ability of macrophages to export recycled iron from senescent rbcs, which constitute the primary source of iron in the plasma. In addition, a high concentration of hepcidin in the blood decreases the transport of iron out of intestinal epithelial cells, further limiting iron in the blood.

Control of hepcidin expression
Hepcidin is synthesized, processed to an active form, and secreted predominantly by hepatocytes (6, 7). The expression of hepcidin is mediated through the bone morphogenetic protein (BMP) and JAK2/STAT3 signaling pathways (Figure 1). Under nonpathological conditions, iron levels in the body upregulate hepcidin expression. Although the underlying mechanisms are poorly understood, recent studies have documented the essential roles of hemojuvelin (HJV), hereditary hemochromatosis protein (HFE), transferrin receptor 2 (TfR2), and matrkapase-2 (MT2, encoded by the gene TMPRSS6) in the process of hepcidin regulation in humans and animal models as well as of BMP6, neogenin, and BMP receptors (ActRIIA/ALK2/ALK3) in animal models (8–17).

Intact BMP signaling is essential for hepcidin expression. The canonical BMP-signaling pathway is initiated upon BMP binding to a BMP receptor complex on the cell surface, which activates the receptor kinase to phosphorylate the cytoplasmic proteins SMAD1, SMAD5, and SMAD8. These phosphorylated, receptor-regulated SMADs then form transcription factor complexes with SMAD4, consisting of receptor-regulated SMADs and SMAD4, that translocate into the nucleus to induce the transcription of target genes such as hepcidin (18). In mice, liver-specific disruption of SMAD4 or the BMP receptors ALK2 or ALK3 markedly decreased hepcidin expression, resulting in iron overload (15, 19).

BMP6. At least 20 BMPs are expressed in mammals. In vitro studies reveal that BMP2, -4, -5, -6, -7, and -9 can robustly induce BMP signaling and markedly increase hepcidin expression in isolated hepatocytes (11, 20, 21). However, global disruption of Bmp6 in mice reduced hepcidin expression and caused severe iron overload (10, 11), indicating that BMP6 plays a pivotal role in the maintenance of iron homeostasis that cannot be compensated by other BMPs. The importance of BMP6 in regulating hepcidin expression is most likely due to its upregulation by iron in the liver (22–25). BMP6 expression is detected mainly in the nonparenchymal cells of the liver, especially in sinusoidal endothelial cells that are in close contact with the circulation (26). Thus the nonparenchymal cells in the liver likely play an important role in iron homeostasis by acting as a source of BMP6 to modulate hepatic hepcidin expression (Figure 1A). However, the mechanism by which hepatic iron levels regulate BMP6 remains to be determined.

Hepatic HJV is an indispensable BMP coreceptor. HJV (also known as hemochromatosis type 2a [HFE2A]) is a glycosylphosphatidylinositol-linked (GPI-linked) membrane protein. In the liver, HJV is exclusively expressed in hepatocytes (16, 26) and acts as a coreceptor for BMP6 to induce hepcidin expression via the BMP signaling pathway (11, 20, 27), presumably by using ActRIIA in combination with either ALK2 or ALK3 (28). Homozygous or compound heterozygous mutations of HJV in humans markedly reduce hepcidin expression and cause juvenile hemochromatosis (29, 30), one of the most severe forms of the iron overload disorders. In Hjv−/− mice, hepcidin expression was low despite increased BMP6 expression in the liver (25) indicating an essential role for HJV in BMP6 regulation of hepcidin. The increase in hepatic BMP6 expression in these mice results from the severe iron overload. HJV also interacts with neogenin (31). Neogenin is a ubiquitously expressed membrane protein (32). Neogenin deficiency in neogenin mutant mice abolished hepcidin expression and resulted in severe iron overload that is indistinguishable from that in Hjv−/− mice (16). Although these mutant mice died a few weeks after birth, these observations suggest a potential role of neogenin for the proper function of HJV.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2013;123(6):2337–2343. doi:10.1172/JCI67225.
HJV is also expressed in skeletal and heart muscle. In the C2C12 murine myoblast cell line, membrane-bound HJV can be released from cells upon cleavage by the ubiquitously expressed furin, a pro-protein convertase (33, 34). Cleaved soluble HJV is detectable in the serum, and its level in the circulation is elevated upon acute iron deficiency (35, 36). Soluble HJV, which was originally suggested to derive from muscle, binds BMP6 and a variety of other BMPs (11, 20, 37). Soluble HJV has been implicated in suppressing hepcidin expression by acting as a decoy to compete with hepatic HJV for BMP6 (11, 27). More recent studies in conditional knockout mice indicated that only the hepatic HJV is necessary for iron homeostasis (38, 39). However, these results do not rule out the possibility that soluble HJV acts as a suppressor of hepcidin expression.

**Hepcidin regulation by HFE and TfR2**. HFE interacts with TfR2 (40, 41) and both are predominantly expressed in hepatocytes (42). Hereditary hemochromatosis (HH), the most common form of iron overload disease, is most frequently due to a C282Y mutation in HFE, but can also derive from mutations in TfR2 (17). In spite of elevated liver BMP6 expression in Hfe<sup>−/−</sup> or Tfr2<sup>−/−</sup> mice, iron overload is associated with attenuated BMP signaling and decreased hepcidin expression (43, 44). These results imply that HFE and TFR2 do not upregulate BMP6 expression directly. Given that Hfe<sup>−/−</sup> and Tfr2<sup>−/−</sup> mice have lower hepcidin levels for the degree of iron loading, these results also indicate that high BMP6 expression cannot completely compensate for lack of HFE or TFR2.

The mechanism by which HFE and Tfr2 regulate hepcidin expression is still controversial. One study indicated that HFE and TFR2 act as a complex to facilitate hepcidin expression through the same pathway, in which HFE is a limiting factor (40). Disruption of either Hfe or Tfr2 in mice attenuated the BMP signaling (43, 44). Other studies showed that disruption of both Hfe and Tfr2 in mice causes even lower hepcidin expression and more severe hepatic iron overload than inactivation of a single gene, which implies that Hfe and Tfr2 regulate hepcidin expression through distinct pathways (45, 46). A recent in vitro study suggested that both HFE and TfR2 bind HJV (47). In conjunction with the findings that iron loaded transferrin (Tf) stabilizes TfR2 by redirecting it to a recycling pathway (48), we hypothesize that HFE and TfR2 regulate hepcidin expression by their interaction with HJV. Under conditions of high Tf saturation, the combination of decreased HFE-Tfr1 interaction and the increased stability of TfR2 would stabilize the association of HFE and TfR2 with HJV. Consequently, the complex would facilitate HJV-induced hepcidin expression (Figure 1A). Conversely, during iron deficiency, Tf saturation would decrease. The interaction between HFE and TFR1 would increase, TfR2 levels would decline due to more rapid turnover, and the association of HFE and TFR2 with HJV would decrease, leading to a downregulation of hepcidin expression (Figure 1B). This hypothesis remains to be tested in vivo.
MT2 is a key suppressor of hepcidin expression. MT2 is a membrane serine protease that is expressed mainly in the liver (49). MT2 mutations in humans or lack of MT2 in mice result in increased hepcidin expression and iron refractory iron deficiency anemia (IRIDA) (12–14). Thus, MT2 is a key negative regulator of hepcidin expression. MT2 interacts with HJV, which is the only known substrate of MT2, and both are expressed in hepatocytes. MT2 likely suppresses hepcidin expression by releasing HJV from hepatocytes, thus abolishing HJV’s ability to act as a BMP coreceptor (50). Iron deficiency anemia (IDA) resulting from mutations in MT2 is dependent on the presence of functional BMP6, implying that MT2 affects the BMP-signaling pathway (51). MT2 also interacts with neogenin and forms a tertiary complex with both neogenin and HJV. Studies in transfected cells indicated that the MT2-neogenin complex facilitates HJV cleavage by MT2 (52). Additionally, recent studies implicate MT2 as a genetic modifier of the HFE–hemichromatosis phenotype (53, 54). In Hfe<sup>−/−</sup> mice, heterozygous loss of Tmprss6 reduced systemic iron overload, and homozygous loss caused systemic iron deficiency and elevated hepatic hepcidin expression (53). In patients with homozygous C282Y mutation in the HFE gene, A736V MT2 polymorphism was negatively associated with the penetrance and clinical expression of HH (54).

Studies on the regulation of MT2 expression in response to iron levels in the body are just emerging, and some results are contradictory. In rats, acute iron deficiency increased the level of MT2 protein but exhibited no effect on its message expression (26). Increased MT2 is expected to suppress hepcidin expression by cleaving plasma membrane HJV in hepatocytes (Figure 1B). Other groups report that the transcription of the MT2-encoding gene Tmprss6 can be upregulated either by BMP6 through the BMP-signaling pathway (55) or by hypoxia through both HIF-1α and HIF-2α (56, 57). Additionally, a recent study showed that hepatocyte growth factor activator inhibitor type 2 (HAI-2) can form a complex with MT2 to inhibit the enzymatic activity of MT2, which indirectly influences the expression of hepatic hepcidin (58). Despite these important observations, the precise mechanism for the regulation of MT2 expression by iron remains to be elucidated.

Hepcidin and the anemia of chronic disease

The anemia of chronic disease (ACD) is usually associated with disorders leading to chronic immune activation. These disorders include but are not limited to chronic kidney disease, chronic infection, diabetes mellitus, severe trauma, rheumatoid arthritis, Crohn’s disease, and cancer (59, 60). Patients with ACD have low plasma iron and Tf saturation, despite normal or elevated body iron stores (61). The mechanism underlying this disrupted-iron balance involves hepcidin. Both acute and chronic inflammatory stimuli induce hepcidin expression. IL-6 or LPS induced hepcidin expression in human hepatocytes (62, 63). In mouse hepatocytes, hepcidin expression was induced by IL-6, IL-1α, and IL-1β (64). In vivo studies highlight the role for IL-6 in promoting inflammation-driven hepcidin expression. The induction of hepcidin and subsequent hypoferremia were observed in wild-type mice that were treated with turpentine as an inflammation model, but not in IL-6–knockout mice under the same treatment (62), implying that the upregulation of hepcidin during inflammation is mediated through IL-6. In a study to measure the response of hepcidin to IL-6 in humans, volunteers were infused with recombinant IL-6. IL-6 stimulated urinary hepcidin excretion and induced hypoferremia, demonstrating a similar response to that in mice (62). The signal for hepatic hepcidin induction by inflammatory stimuli relies on the stimulation of the JAK2/STAT3 pathway (65–67). In response to an inflammatory stimulus, elevated IL-6 binds to its cellular receptor, which activates JAK2 to phosphorylate STAT3. Activated STAT3 translocates into the nucleus and induces hepcidin expression through binding to the STAT3 response element in the hepcidin promoter (Figure 1C). The anemia results from the downregulation of FPN1, which reduces iron efflux from both enterocytes and macrophages into the circulation and thus decreases the available iron for erythropoiesis (5).

Liver-specific knockout of Smad4 results in blunted hepcidin response after IL-6 administration, implying that an intact BMP/SMAD signaling pathway is necessary for the upregulation of hepcidin by the inflammatory pathway (19). Blocking BMP signaling inhibits IL-6–induced hepcidin expression in HepG2 cells (27). Consistently, a recent study indicates that inflammation also induces hepatic expression of activin B, a cytokine of the TGF-β superfamily, which increases hepcidin expression by activating the BMP-signaling pathway, likely via a type I BMP receptor (68).

Hepcidin and iron regulation in β-thalassemia

The regulation of iron by hepcidin is of particular clinical importance in anemia with iron loading, which occurs in β-thalassemia, a disorder caused by aberrations in the expression of hemoglobin β chains. When anemia occurs with iron loading, two opposite hepcidin-regulatory signals coexist: anemia associated with ineffective erythropoiesis being inhibitory and iron loading being stimulatory.

β-Thalassemia represents one of the most common inherited forms of chronic anemia. The most important clinical manifestation of β-thalassemia is microcytic, suggesting a dominant negative effect of an erythroid regulator (69). The anemia in β-thalassemia is attributed to intramedullary hemolysis, increased destruction of existing RBCs, and shortened RBC survival. However, the major cause of morbidity and mortality in β-thalassemias is iron overload, with iron-induced cardiomyopathy being the leading cause of death in transfusion-dependent thalassemia (70).

Individuals with β-thalassemia major need blood transfusions every two to five weeks to sustain life. The amount of iron loading in these patients mainly depends on the volume of blood transfused in addition to ineffective erythropoiesis. During transfusion intervals, hemoglobin levels gradually decrease and ineffective erythropoiesis increases. Increased erythropoietic activity reduces hepcidin and increases iron absorption, exacerbating the iron overload (71).

In contrast, people with β-thalassemia intermedia are not dependent on transfusion therapy. Their iron overload is a result of increased iron absorption from the small intestine due to ineffective erythropoiesis. They absorb three to four times more iron than unaffected individuals and have high plasma iron and low hepcidin levels (72, 73). A mouse model of β-thalassemia intermedia (th/+) has a similar phenotype (74, 75). These mice are heterozygous for mutations in both the β<sup>minor</sup> and β<sup>major</sup> genes. The finding that ineffective erythropoiesis can override iron signals suggests the existence of an erythropoietic signal that inhibits hepcidin expression.

Erythropoietic activity suppresses hepcidin expression

Iron metabolism and erythropoiesis are inextricably interconnected. Erythrocytes require iron incorporation into the heme group to carry oxygen. Without adequate iron, the maturation...
of erythrocytes is impaired, resulting in microcytic hypochromic anemia. Most of the iron for erythropoiesis comes from catabolism of senescent red blood cells in the reticuloendothelial system, with effective erythropoiesis counterbalancing the loss of aged blood cells. Erythropoiesis is downregulated by erythropoietic stimuli such as anemia, hypoxia, and synthetic erythropoietin (EPO) administration (76, 77). Physiologically, increased systemic erythropoiesis is a major adaptation to hypoxia. The reduced tissue oxygen level is sensed mainly by the kidney, resulting in increased production of EPO, a key regulator and whether it is controlled by EPO or erythropoiesis depends on increased erythropoietic activity (91, 92). Thus, the precise mechanism by which hypoxia suppresses hepcidin expression remains to be determined.

Development of assays to quantify hepcidin

Several groups have established assays to measure hepcidin levels in plasma because of its importance in iron homeostasis and iron distribution in the body. Abnormally low hepcidin levels contribute to the pathological accumulation of iron in HH as well as in ineffective erythropoiesis, exemplified by β-thalassemia. High hepcidin levels are indicative of the ACD and of IRIDA. Mass spectrometry assays are based on the identification of the 25–amino acid form of hepcidin in plasma (93–97). This form of hepcidin binds to FPN1 and targets FPN1 for degradation in the lysosome (5). Comparisons between hepcidin mRNA levels and the levels of the 25–amino acid processed form of hepcidin suppresses hepcidin expression in hepatocytes independently of iron stores in the body (77). Thus, hypoxia may play a role in iron regulation in patients with anemia accompanied by ineffective erythropoiesis. The central mediators of hypoxia-induced erythropoiesis are HIF proteins, of which HIF-1α and HIF-2α are best characterized. HIF proteins are heterodimers of one α and one β subunit. Oxygen, iron, and ascorbate-dependent prolyl-4-hydroxylase domain-containing proteins (PHDs) all regulate the stability of the α subunit. Under normoxic conditions, PHDs use 2-oxoglutarate as a cofactor for hydroxylation of HIF α-subunits. Hydroxylated HIF α-subunits are recognized by the von Hippel–Lindau tumor suppressor (pVHL), which acts as a component of an E3 ubiquitin ligase complex (86, 87). The subsequent ubiquitination targets HIF α subunits for proteosomal degradation. During hypoxic conditions, the hydroxylation is inhibited, thus increasing the stability of the HIF α subunits, and high HIF levels activate a broad range of genes required for hypoxia adaptation.

HIF-1α was discovered when the mechanism by which hypoxia induces the production of EPO was examined (88, 89). HIF-1α binds to the enhancer element of the EPO gene and activates its transcription in response to hypoxia. Further, HIF-1α negatively regulates hepcidin expression by binding to the hepcidin promoter in vivo and reduces hepcidin expression in the mouse liver (90). The dietary iron deficiency–induced hepcidin downregulation is partially blunted in hepatocyte-specific Hif-1α–knockout mice. However, two independent groups reported that hepcidin suppression is not directly regulated by either HIF-1α or HIF-2α, but depends on increased erythropoietic activity (91, 92).

Table 1

<table>
<thead>
<tr>
<th>Genetic diseases involving abnormal hepcidin levels</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease</strong></td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>HH</td>
</tr>
<tr>
<td>Type 1</td>
</tr>
<tr>
<td>Type 2a</td>
</tr>
<tr>
<td>Type 2b</td>
</tr>
<tr>
<td>Type 3</td>
</tr>
<tr>
<td>IRIDA</td>
</tr>
<tr>
<td>αα- and β-thalassemia</td>
</tr>
<tr>
<td>DMT1 iron overload</td>
</tr>
<tr>
<td>Acrileplasmninemia</td>
</tr>
<tr>
<td>Atransferrinemia</td>
</tr>
</tbody>
</table>
The regulation of hepcidin levels to control iron overload have mainly focused on ameliorating iron overload in β-thalassemia. Overexpression of hepcidin in a mouse model of β-thalassemia intermedia not only prevented iron overload but also improved anemia (74). Modulation of hepcidin pathways in β-thalassemic mice through Tf injection increased hepcidin expression, reduced serum EPO levels, and improved anemia (109). Downregulation of TMPRSS6 using an RNAi strategy or the second generation anti-sense oligonucleotides (ASOs) in murine models of Hfe HH and β-thalassemia intermedia induced hepcidin expression and lessened iron loading of tissues in both models. Moreover the anemia in the Hbb (th3/+) mice was improved with increased erythropoiesis and rbc survival (110, 111).

Modulation of the BMP signaling pathway has been utilized to regulate hepcidin expression. A soluble form of HJV (HJV.Fc) has been used to compete with the endogenous cell–associated form of HJV to inhibit hepcidin expression in mice (27) or in rats (112). Injection of BMP6 increased BMP signaling and hepcidin expression in mice. Unfortunately, the BMP6 injections resulted in peritoneal calcifications (113). Additionally, a recent study indicated that the BMP signaling pathway could be a promising target for the treatment of ACD. Administration of LDN-193189 (a BMP type I receptor inhibitor) or ALK3-Fc (a soluble form of ALK3) prevented the increase in hepcidin expression, the reduction of serum iron, and the development of microcytic anemia in mice caused by induction of inflammation using IL-6 or turpentine (114). Heparin was used to decrease hepcidin levels through the BMP signaling pathway. A combination of in vitro results, in vivo murine studies, and a limited study in humans indicated that heparin reduces hepcidin expression presumably by binding to BMP6 to reduce BMP-mediated signaling (115). Alteration of BMP signaling may not be an ideal way to alter hepcidin signaling chronically because BMP signaling alters many other metabolic pathways in the body.

The STAT3 pathway is another target for modulating hepcidin expression. An inhibitor of STAT3 phosphorylation was able to inhibit hepcidin expression in mice and could be a potential candidate for the treatment of anemia associated with high hepcidin levels (116, 117). Similarly, an anti–IL-6 receptor antibody has been used to reduce hepcidin levels in patients with Castleman’s disease, characterized by high IL-6 levels (118, 119). Lowering inflammation and hepcidin levels during active infections has the potential to increase the proliferation of the pathogenic organism by supplying it with more iron.

In summary, the rapid progress in the understanding of how hepcidin controls iron homeostasis and the intense research as to how hepcidin levels can be altered promise new therapies in the future for diseases exacerbated by iron overload or iron depletion.

## Acknowledgments

This work was supported by NIH grants DK054488 (to C.A. Enns), DK072166 (to C.A. Enns), and DK080765 (to A.S. Zhang) and by the Collins Medical Trust (to N.N. Zhao). We wish to thank the reviewers for the careful reading of the manuscript.

## Address correspondence to:

Caroline A. Enns or An-Sheng Zhang, Department of Cell and Developmental Biology, L215, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA. Phone: 503.494.5845; Fax: 503.494.4253; E-mail: ennsca@ohsu.edu (C.A. Enns). Phone: 503.494.5846; Fax: 503.494.4253; E-mail: zhanga@ohsu.edu (A.-S. Zhang).

## Table 2

<table>
<thead>
<tr>
<th>Target</th>
<th>Reagent</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMPRSS6</td>
<td>siRNA</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>ASOs</td>
<td>111</td>
</tr>
<tr>
<td></td>
<td>BMP6</td>
<td>55</td>
</tr>
<tr>
<td>BMPR</td>
<td>dorsomorphin</td>
<td>120</td>
</tr>
<tr>
<td></td>
<td>LDN193189</td>
<td>112, 114</td>
</tr>
<tr>
<td>FPN1</td>
<td>minihepcidin</td>
<td>104, 105</td>
</tr>
<tr>
<td>BMP6</td>
<td>s-HJV.Fc</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>anti-BMP6</td>
<td>11</td>
</tr>
<tr>
<td>BMP6?</td>
<td>Heparin</td>
<td>115</td>
</tr>
<tr>
<td>STAT3</td>
<td>AG490</td>
<td>116, 117</td>
</tr>
<tr>
<td>IL-6R</td>
<td>anti–IL-6R (tocilizumab)</td>
<td>118, 119</td>
</tr>
<tr>
<td>hepcidin</td>
<td>Spiegelmer NOX-H94</td>
<td>108</td>
</tr>
<tr>
<td></td>
<td>Anti-hepcidin</td>
<td>107</td>
</tr>
</tbody>
</table>

Hepcidin is a prime target for the regulation of iron homeostasis in the body because of its specificity in binding FPN1 and the lack of other biological functions aside from its weak defensin-like activity. The iron overload seen in HH is due to inappropriately low levels of hepcidin (Table 1). A short lipophilic peptide, termed minihepcidin (PR65), was designed to mimic hepcidin and, unlike hepcidin, it can be administered orally. This compound was tested in mouse models of iron overload, and it lack of other biological functions aside from its weak defensin-like activity. The iron overload seen in HH is due to inappropriately low levels of hepcidin (Table 1). A short lipophilic peptide, termed minihepcidin (PR65), was designed to mimic hepcidin and, unlike hepcidin, it can be administered orally. This compound was tested in mouse models of iron overload, and it...
The Journal of Clinical Investigation


http://www.jci.org   Volume 123   Number 6   June 2013


